問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chung Shan Medical University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 402Taichung CityTaichung South

Recruiting Trial

175Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

500Cases

2024-11-29 - 2027-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-03-28 - 2026-08-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-08-26 - 2026-07-23

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting4Sites

Terminated3Sites

2015-10-01 - 2017-07-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated4Sites

陳彥旭
Kaohsiung Municipal Gangshan Hospital

未分科

2021-04-01 - 2024-03-01

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2021-04-01 - 2024-05-14

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2021-04-09 - 2024-12-31

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2016-02-01 - 2017-12-31

Phase IV

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Terminated8Sites

2024-07-01 - 2027-12-31

Phase III

Active
Studies of Heart & Kidney Protection with BI 690517 in combination with empagliflozin: A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease

  • Condition/Disease

    chronic kidney disease

  • Test Drug

    placebo ‧ BI 690517 Empagliflozin

Participate Sites
23Sites

Recruiting23Sites

2020-05-15 - 2023-02-09

Phase III

A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A

  • Condition/Disease

    Severe Hemophilia A

  • Test Drug

    BIVV001/250 IU BIVV001/500 IU BIVV001/1000 IU BIVV001/2000IU

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

1 26 27 28 29 30 50
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB